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1 It has been suggested that the tachycardic response to 5-hydroxytryptamine (5-HT) in the spinal-
transected cat is mediated by ‘5-HT1-like’ receptors since this eect, being mimicked by 5-
carboxamidotryptamine (5-CT), is not modified by ketanserin or MDL 72222, but it is blocked by
methiothepin, methysergide or mesulergine. The present study was set out to reanalyse this suggestion in
terms of the IUPHAR 5-HT receptor classification schemes proposed in 1994 and 1996.
2 Intravenous (i.v.) bolus injections of the tryptamine derivatives, 5-CT (0.01, 0.03, 0.1, 0.3, 1, 3, 10 and
30 mg kg71), 5-HT (3, 10 and 30 mg kg71) and 5-methoxytryptamine (3, 10 and 30 mg kg71) as well as the
atypical antipsychotic drug, clozapine (1000 and 3000 mg kg71) resulted in dose-dependent increases in
heart rate, with a rank order of agonist potency of 5-CT44 5-HT4 5-methoxytryptamine44 clozapine.
3 The tachycardic eects of 5-HT and 5-methoxytryptamine were dose-dependently antagonized by i.v.
administration of lisuride (30 and 100 mg kg71), ergotamine (100 and 300 mg kg71) or mesulergine (100,
300 and 1000 mg kg71); the highest doses of these antagonists used also blocked the tachycardic eects of
5-CT. Clozapine (1000 and 3000 mg kg71) did not aect the 5-HT-induced tachycardia, but attenuated,
with its highest dose, the responses to 5-methoxytryptamine and 5-CT. However, these doses of
clozapine as well as the high doses of ergotamine (300 mg kg71) and mesulergine (300 and 1000 mg kg71)
also attenuated the tachycardic eects of isoprenaline. In contrast, 5-HT-, 5-methoxytryptamine- and 5-
CT-induced tachycardia were not significantly modified after i.v. administration of physiological saline
(0.1 and 0.3 ml kg71), the 5-HT1B/1D receptor antagonist, GR127935 (500 mg kg71) or the 5-HT3/4
receptor antagonist, tropisetron (3000 mg kg71).
4 Intravenous injections of the 5-HT1 receptor agonists, sumatriptan (30, 100 and 300 mg kg71) and
indorenate (300 and 1000 mg kg71) or the 5-HT4 receptor (partial) agonist cisapride (300 and
1000 mg kg71) were devoid of eects on feline heart rate per se and failed to modify significantly 5-
HT-induced tachycardic responses.
5 Based upon the above rank order of agonist potency, the failure of sumatriptan, indorenate or
cisapride to produce cardioacceleration and the blockade by a series of drugs showing high anity for
the cloned 5-ht7 receptor, the present results indicate that the 5-HT receptor mediating tachycardia in the
cat is operationally similar to other putative 5-HT7 receptors mediating vascular and non-vascular
responses (e.g. relaxation of the rabbit femoral vein, canine external carotid and coronary arteries, rat
systemic vasculature and guinea-pig ileum). Since these responses represent functional correlates of the
5-ht7 gene product, the 5-HT7 receptor appellation is reinforced. Therefore, the present experimental
model, which is not complicated by the presence of other 5-HT receptors, can be utilized to characterize
and develop new drugs with potential agonist and antagonist properties at functional 5-HT7 receptors.
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Introduction
5-Hydroxytryptamine (5-HT) elicits complex changes in the
cardiovascular system comprising bradycardia or tachycardia,
hypotension or hypertension and vasodilatation or vasocon-
striction (for reviews, see Saxena & Villalo´n, 1990; 1991). In
most species, bradycardia induced by 5-HT is mediated by 5-
HT3 receptors, via the activation of the von Bezold Jarisch
reflex; in marked contrast, 5-HT-induced tachycardia is no-
toriously species-dependent and is mediated, directly or in-
directly, either by ‘5-HT1-like’ (cat), 5-HT2 (rat, dog), 5-HT3
(rabbit, dog) and 5-HT4 (pig, human) receptors or by tyra-
mine-like (guinea-pig) or unidentified mechanisms (Saxena,
1986; Saxena & Villalo´n, 1990; 1991).
The so called ‘5-HT1-like’ receptors mediating tachycardia
in the cat are potently stimulated by 5-carboxamidotryptamine
(5-CT) and blocked by methiothepin and methysergide (Sax-
ena et al., 1985; Saxena, 1988). However, it is noteworthy that
these receptors do not satisfactorily fulfill some classification
requirements for the 5-HT1 type, including insensitivity to
stimulating doses of RU 24969 and 8-OH-DPAT at typical 5-
HT1-like receptor-mediated responses (e.g. constriction of
porcine carotid arteriovenous anastomoses; Saxena & Villalo´n,
1990), blockade by mesulergine (Saxena, 1988), an ergoline
devoid of interactions with the 5-HT1 receptor family (Hoyer
et al., 1994), and inconsistency with a negative coupling to
adenylyl cyclase (Hoyer et al., 1994). These cardiac receptors,
consequently, are dierent from the typical 5-HT1-like recep-
tors mediating vasoconstriction, a response usually associated
with a decrease in cyclic AMP (Sumner et al., 1992), but are
similar to those mediating direct relaxation of vascular and
non-vascular smooth muscle, a response that involves an in-
crease in cyclic AMP (for references see Saxena & Villalo´n,
1990; Martin, 1994).
While evidence is emerging that sumatriptan-sensitive 5-
HT1-like receptors mediating vasoconstriction resemble 5-
HT1Db/1Da receptors (De Vries et al., 1996; Villalo´n et al., 1996),
presently known as a 5-HT1B/1D receptors (Hartig et al., 1996),
the recently cloned 5-ht7 receptor (e.g. Bard et al., 1993; Ruat
et al., 1993) seems to be a suitable candidate for responses1Author for correspondence.
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mediated by the atypical, sumatriptan-insensitive 5-HT1-like
receptors. Indeed, the cloned 5-ht7 receptor is positively cou-
pled to adenylyl cyclase and binding studies show that the
cloned 5-ht7 receptor displays high anities for 5-CT, 5-HT,
methiothepin, mesulergine and methysergide, but relatively
low anities for RU 24969, 8-OH-DPAT and sumatriptan
(Hoyer et al., 1994).
In the light of these findings, the present study was set out to
investigate the operational characteristics of the 5-HT recep-
tors mediating tachycardia in the spinal cat, with particular
emphasis on verifying if these receptors display the pharma-
cological profile of the cloned 5-ht7 receptor. Hence, the drugs
employed included agonists and/or antagonists at 5-HT1, 5-
HT2, 5-HT3 and 5-HT4 receptors, as well as some compounds
with high anity for the cloned 5-ht5, 5-ht6 and/or 5-ht7 re-
ceptors (see Hoyer et al., 1994).
Methods
General
Forty one cats of either sex, not selected for breed (2.5 – 4.0 kg)
were fasted overnight and initially anaesthetized with sodium
pentobarbitone (30 mg kg71, i.v.). Left femoral vein and ar-
tery were cannulated for, respectively, drug injections and the
measurement of aortic blood pressure by a Statham pressure
transducer (P23 ID). Heart rate was obtained by triggering a
tachograph (Grass Instruments Co., Quincy, MA, USA; model
7P4) with the ECG signals. Blood pressure and heart rate were
recorded simultaneously by a model 7D Grass polygraph
(Grass Instrument Co., Quincy, MA, U.S.A.). The animals
were then given an additional dose of pentobarbitone (10 –
15 mg kg71, i.v.) and intubated with an endotracheal tube for
artificial ventilation with room air, by a Palmer ventilation
pump (rate: 20 strokes min71; stroke volume: 13 – 16 ml kg71).
Subsequently, both vagosympathetic trunks and the spinal
cord (at the level of C1 –C2) were sectioned in all animals, as
previously described (Saxena et al., 1985; Saxena, 1988).
Experimental protocols
After the cats had been in a stable haemodynamic condition
for at least 60 min, baseline values of blood pressure and heart
rate were determined. Then, the animals were divided into two
groups.
The first group (n=34) received consecutive i.v. bolus in-
jections, every 5 to 10 min, of 5-HT (3, 10 and 30 mg kg71), 5-
methoxytryptamine (3, 10 and 30 mg kg71) and isoprenaline
(0.01, 0.03 and 0.1 mg kg71) and the changes produced in
blood pressure and heart rate were noted. At this point, the
animals were divided into six subgroups. Four subgroups were
treated, by use of a cumulative dose schedule, with either
physiological saline (0.1 and 0.3 ml kg71; n=5), lisuride (30
and 100 mg kg71; n=6), ergotamine (100 and 300 mg kg71;
n=6) or mesulergine (100, 300 and 1000 mg kg71; n=6). The
fifth subgroup (n=6) was given clozapine (1000 and
3000 mg kg71) following a sequential (not cumulative) dosing
because it produced an immediate short-lasting tachycardic
response by itself. The sixth subgroup (n=5) was treated with
GR127935 (500 mg kg71) and, subsequently, with tropisetron
(3000 mg kg71). The responses to i.v. injections of 5-HT, 5-
methoxytryptamine and isoprenaline, at the doses and se-
quence listed above, were elicited again 10 min after each dose
of physiological saline or the above compounds.
The second group (n=7) received consecutive i.v. injections
of 5-HT (3, 10 and 30 mg kg71) and isoprenaline (0.01, 0.03
and 0.1 mg kg71) and the changes in blood pressure and heart
rate were noted. The animals were then divided into two
subgroups. The first subgroup (n=4) was given, sequentially,
i.v. injections of the 5-HT1 receptor agonist, indorenate (300
and 1000 mg kg71 spaced by 5 min) followed by the 5-HT4
receptor (partial) agonist, cisapride (300 and 1000 mg kg71
spaced by 5 min) and the second subgroup (n=3) was treated
with sequential i.v. injections of the 5-HT1 receptor agonist,
sumatriptan (30, 100 and 300 mg kg71 spaced by 5 min). After
each treatment and dose, the responses to 5-HT and isopre-
naline were reanalysed.
Subsequently, each of the above 8 subgroups received, at
the end of their corresponding protocol, i.v. injections of 5-CT
at cumulative total dose levels of 0.03, 0.1, 0.3, 1, 3, 10 and
30 mg kg71 every 5 – 7 min. The changes in heart rate and
blood pressure, produced after each dose of 5-CT, were noted.
Lastly, in at least three cats of each of the above eight sub-
groups (see Results section), the highest dose used of saline or
the corresponding drug was administered once again in an
attempt to investigate which compounds could reverse the
tachycardia elicited by the highest dose of 5-CT (30 mg kg71),
as previously described for methysergide (Saxena et al., 1985).
With the exception of 5-CT (see above), the dose-intervals
between the dierent doses of agonists ranged between 1 and
10 min, as in each case we waited until the heart rate had
returned to baseline values. For the antagonists, as well as for
indorenate, cisapride and sumatriptan, a period of 10 min was
allowed to elapse before the dose-response curves for the
agonists were elicited again. The dosing with 5-HT, 5-meth-
oxytryptamine, isoprenaline, sumatriptan, indorenate, cisa-
pride and clozapine was sequential, whilst that for 5-CT and
the rest of the antagonists was cumulative.
Data presentation and statistical analysis
All data in the text and figures are presented as mean+s.e.-
mean and these were analysed by a computer programme
(Saxena, 1985). The agonist-induced increases in heart rate just
before and after a particular dose of saline or antagonist drug
within one group of animals were compared by Student
Newman-Keuls’ test, once an analysis of variance (randomized
block design) had revealed that the samples represented dif-
ferent populations. Furthermore, the increases in heart rate by
5-HT and isoprenaline before and after sumatriptan
(430 mg kg71), indorenate (1300 mg kg71) or cisapride
(1300 mg kg71), given cumulatively, were compared by using
paired Student’s t test. Finally, the tachycardic responses to 5-
CT in the dierent groups of animals were compared by using
unpaired Student’s t test. A P value of 0.05 or less (two-tailed)
was considered statistically significant.
Drugs
Apart from the anaesthetic (sodium pentobarbitone), the drugs
used in the present study (obtained from the sources indicated)
were the following: 5-hydroxytryptamine creatinine sulphate
(Sigma Chemical Company, St. Louis, MO, U.S.A.); lisuride
hydrogen maleate, isoprenaline hydrochloride, 5-methoxy-
tryptamine hydrochloride and 5-carboxamidotryptamine
maleate (Research Biochemicals Int., Natick, MA, U.S.A.);
sumatriptan succinate (gift: Prof. P.P.A. Humphrey, Glaxo
Institute of Applied Pharmacology, Cambridge, U.K.); N-[4-
methoxy-3-(4-methyl-1-piperazinyl) phenyl]72'-methyl-4'-(5-
methyl-1,2,4-oxadiazol-3-yl) [1,1,-biphenyl]74-carboxamide
hydrochloride monohydrate (GR127935; gift: Dr M. Skingle,
Glaxo Group Research Limited, Ware, Herts, U.K.); tropise-
tron (ICS 205-930), clozapine base, mesulergine hydrochloride
and ergotamine tartrate (gift: Sandoz A.G., Basel, Switzer-
land); indorenate (5-methoxytryptamine-b-methylcarboxylate
hydrochloride or TR3369; gift: Prof. Dr. E. Hong, CINVES-
TAV-IPN, Mexico City, Mexico); and cisapride (gift: Janssen
Pharmaceutica, Beerse, Belgium). All compounds were dis-
solved in distilled water. When needed, 4% (w/v) ascorbic acid
(clozapine) or 5% (v/v) dimethylsulphoxide (DMSO) (lisuride)
was added; these vehicles had no eect on the haemodynamic
variables or the agonist-induced responses. The doses men-
tioned in the text refer to the salts of substances, except in the
case of all agonists and clozapine, where they refer to the free
base.
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Results
Initial blood pressure and heart rate changes by 5-HT
receptor agonists
Baseline values of mean arterial blood pressure and heart rate
in the forty one cats were, respectively, 84+3 mmHg and
184+35 beats min71. The changes induced in mean arterial
blood pressure by the agonist drugs were: 5-HT (72+1,
+3+4 and +15+5 mmHg after 3, 10 and 30 mg kg71, re-
spectively; n=41), 5-methoxytryptamine (71+2, +7+4 and
+23+4 mmHg after 3, 10 and 30 mg kg71, respectively;
n=34), 5-CT (71+17,713+5,717+6 and720+7 mmHg
after 0.03, 0.1, 0.3 and 1 mg kg71, with 3, 10 and 30 mg kg71
producing no subsequent change; n=5, i.e. saline-treated ani-
mals), sumatriptan (712+12, +17+9, +3+2 mmHg after
30, 100 and 300 mg kg71, respectively; n=3), indorenate
(75+7 and 73+5 mmHg after 300 and 1000 mg kg71, re-
spectively; n=4), cisapride (71+2 and 77+3 mmHg after
300 and 1000 mg kg71, respectively; n=4) and clozapine
(79+5 and 718+5 mmHg after 1000 and 3000 mg kg71,
respectively; n=6). It should be pointed out that these eects
were not evaluated further because in spinal cats the baseline
blood pressure is low and, consequently, the hypotensive re-
sponses produced by the above agonists were smaller and not
strictly dose-dependent (see above).
The onset of the increases in heart rate induced by the
agonists under study was immediate. Figure 1 shows that
isoprenaline, 5-CT, 5-HT, 5-methoxytryptamine and clozapine
caused dose-dependent increases in heart rate; in contrast,
sumatriptan, indorenate and cisapride, at the doses tested,
failed to increase feline heart rate. Isoprenaline was about 1.5
log units more potent than 5-CT, which was itself distinctly
more potent (1.5 log units) than 5-HT and 5-methoxytrypta-
mine; clozapine was the least potent. Thus, the apparent rank
order of agonist potency was: isoprenaline44 5-CT44 5-
HT4 5-methoxytryptamine44 clozapine.
The duration of tachycardic eects of agonist drugs (ex-
cept 5-CT) was relatively short: isoprenaline (3.9+0.2,
4.8+0.2 and 6.2+0.2 min after 0.01, 0.03 and 0.1 mg kg71,
respectively), 5-HT (2.6+0.2, 4.6+0.2 and 7.0+0.3 min
after 3, 10 and 30 mg kg71, respectively), 5-methoxytrypta-
mine (2.3+0.2, 3.5+0.2 and 5.2+0.2 min after 3, 10 and
30 mg kg71, respectively) or clozapine (2.1+1.0 and 3.0+1.0
after 1000 and 3000 mg kg71, respectively). Furthermore, the
5-CT-induced tachycardia has been shown to last longer
than 1 h (Saxena et al., 1985; Saxena, 1988) and, therefore,
as expected, no recovery was observed with 5-CT during the
dosing intervals (5 – 7 min) or for at least 10 min after the
last dose.
Eect of physiological saline and 5-HT receptor
antagonists on the tachycardic responses induced
by 5-HT, 5-methoxytryptamine and isoprenaline
The eects of physiological saline or lisuride on the ta-
chycardic responses induced by 5-HT, 5-methoxytryptamine
and isoprenaline are depicted in Figure 2. No evidence of
tachyphylaxis was observed since the responses to these
agonists, at the doses and time intervals (330 min) used in
the present study, were reproducible and remained essen-
tially unchanged in control animals receiving two doses (0.1
and 0.3 ml kg71, i.v.) of physiological saline (Figure 2a). In
contrast, the administration of low doses (30 and
100 mg kg71, i.v.) of lisuride potently and dose-dependently
antagonized the tachycardic responses induced by 5-HT and
5-methoxytryptamine; this blockade was specific as lisuride
did not alter isoprenaline-induced tachycardia (Figure 2b).
Ergotamine (100 and 300 mg kg71) and mesulergine (100,
300 and 1000 mg kg71) also produced a dose-dependent
blockade of the tachycardic responses to 5-HT and 5-
methoxytryptamine (Figure 3a and b, respectively). How-
ever, the blockade produced by the high doses of ergota-
mine (300 mg kg71) and mesulergine (300 and 1000 mg kg71)
was not specific as they also attenuated the tachycardic
eects of isoprenaline (Figure 3a and b). Moreover, the
atypical antipsychotic drug, clozapine (1000 and
3000 mg kg71), did not aect 5-HT-induced tachycardia, but
significantly blocked, at its highest dose, the responses to 5-
methoxytryptamine. However, these doses of clozapine also
attenuated the tachycardic eects of isoprenaline
(Figure 4a).
The apparent order of potency for blockade of both 5-HT-
and 5-methoxytryptamine-induced tachycardic responses was
ergotamine5 lisuride4 mesulergine4 clozapine. Finally, as
shown in Figure 4b, the tachycardic responses to 5-HT, 5-
methoxytryptamine and isoprenaline were not significantly
modified after administration of the selective 5-HT1B/1D re-
ceptor antagonist, GR127935 (Skingle et al., 1996) or by the
subsequent administration of tropisetron which, at
3000 mg kg71, is a 5-HT3 and 5-HT4 receptor antagonist
(Villalo´n et al., 1990b; 1991).
Except for an immediate and sustained increase in mean
blood pressure by ergotamine (from 103+9 to
134+13 mmHg, after its highest dose; P50.05), the values of
mean blood pressure and heart rate before and 10 min after
the administration of physiological saline or the above 5-HT
receptor antagonists were not significantly dierent (data not
shown).
Tachycardic eects of 5-HT before and after
administration of indorenate, cisapride or sumatriptan
Since the 5-HT receptor agonists, indorenate, cisapride and
sumatriptan, failed to mimic 5-HT in increasing heart rate (see
Figure 1), we decided to investigate these compounds
(1300 mg kg71 each of indorenate and cisapride in one sub-
group and 430 mg kg71 of sumatriptan in another subgroup)
as potential antagonists of the tachycardic responses to 5-HT.
5-HT (3, 10 and 30 mg kg71) elicited a dose-dependent tachy-
cardia (first subgroup: 5+2, 26+10 and 46+11 beats min71,
n=4, respectively; second subgroup: 7+2, 17+6 and 43+7
beats min71, n=3, respectively). These responses as well as the
tachycardia elicited by isoprenaline (0.01, 0.03 and
0.1 mg kg71) remained unaected after administration of the
above compounds (data not shown).
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Figure 1 Comparative eects of i.v. bolus injections of isoprena-
line (n=41), 5-carboxamidotryptamine (5-CT; n=5), 5-HT (n=41),
5-methoxytryptamine (5-MeO-T; n=34), clozapine (n=6), suma-
triptan (n=3), indorenate (n=4) and cisapride (n=4) on heart rate
(HR) in vagosympathectomized spinal cats. Vertical lines show
s.e.mean.
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Tachycardic eects of 5-CT after physiological saline or
some compounds acting at 5-HT receptors
Figure 5 shows the comparative eects of dierent doses of 5-
CT obtained in cats pretreated with cumulative doses of either
saline (0.3 ml kg71), lisuride (100 mg kg71), ergotamine
(300 mg kg71), clozapine (4000 mg kg71), mesulergine
(1000 mg kg71), GR127935 (500 mg kg71) plus tropisetron
(3000 mg kg71), indorenate (1300 mg kg71) plus cisapride
(1300 mg kg71) or sumatriptan (430 mg kg71). Only lisuride,
mesulergine, ergotamine and clozapine produced a significant
blockade of the responses to 5-CT, with an apparent order of
antagonist potency of ergotamine5 lisuride4mesulergine4
clozapine; in addition, indorenate+cisapride slightly, though
significantly, attenuated the response to the highest dose of
5-CT (30 mg kg71). The remaining compounds produced no
significant eect (Figure 5).
After the tachycardic response to 30 mg kg71 5-CT (given
cumulatively) had been stable for at least 10 min, a subse-
quent administration of the same dose of saline,
GR127935+tropisetron, indorenate+cisapride or sumatrip-
tan (n=3 each) in the corresponding subgroups produced no
further change in heart rate (data not shown). In contrast, 5-
CT-induced tachycardia was significantly (P50.05) decreased
from the prevailing values after i.v. administration of the
same dose of lisuride (717+1%; n=4), ergotamine
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Figure 2 Eects of i.v. bolus injections of (a) physiological saline (n=5) or (b) lisuride (n=6) on tachycardic responses to 5-HT,
5-methoxytryptamine (5-MeO-T) and isoprenaline in vagosympathectomized spinal cats. HR, heart rate. *P50.05 vs the
corresponding control response. Vertical lines show s.e.mean.
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(78+2%; n=4), clozapine (722+4%; n=3) or mesulergine
(725+2%; n=6).
Discussion
In previous studies, Saxena et al. (1985) had proposed that the
tachycardia induced by 5-HT in the cat, being potently mi-
micked by 5-CT and blocked by methysergide, is mediated by
‘5-HT1-like’ receptors on the basis of the resistance to blocking
doses of antagonists at 5-HT2 (ketanserin, ritanserin) and 5-
HT3 (MDL 72222) receptors. However, it is noteworthy that,
in contrast to its constrictor eects via vascular 5-HT1-like
receptors (see Saxena & Villalo´n, 1990), methysergide did not
show any agonist activity at the feline cardiac ‘5-HT1-like’
receptors. Subsequently, Saxena (1988) showed that these
atypical cardiac receptors were unrelated to the 5-HT1A, 5-
HT1B, 5-HT1C (now 5-HT2C) and 5-HT1D subtypes based on: (i)
the blockade, in decreasing order of potency, by methiothepin,
mesulergine and metergoline (an order which does not match
with their corresponding anities for these receptors; Hoyer,
1988); (ii) the low agonist potency of the 5-HT1A receptor
agonist, 8-OH-DPAT; and (iii) the lack of activity of 5-HT1A/1B
receptor agonist, RU 24969.
Certainly, the approach established by the IUPHAR 5-HT
receptor classification scheme (Hoyer et al., 1994) lead us to
conclude that the appellation ‘5-HT1-like’ is no longer re-
garded as appropriate for the 5-HT receptors mediating ta-
chycardia in the cat. The operational approach of the present
study strengthens this view, as the feline cardiac 5-HT
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Figure 3 Eects of i.v. bolus injections of (a) ergotamine (n=6) or (b) mesulergine (n=6) on tachycardic responses to 5-HT,
5-methoxytryptamine (5-MeO-T) and isoprenaline in vagosympathectomized spinal cats. HR, heart rate. *P50.05 vs the
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5-HT7 receptors mediating feline tachycardia 1191C. M. VillaloÂ n et al
receptors were not stimulated by sumatriptan or indorenate
(both agonists at typical 5-HT1-like receptors mediating va-
soconstrictor responses; Saxena & Villalo´n, 1990; Villalo´n et
al., 1990a; Hoyer et al., 1994) and could be blocked by a
series of drugs showing high anity for cloned 5-ht7 recep-
tors. Thus, these cardiac receptors resemble those mediating
smooth muscle relaxation and elevation of adenosine 3':5'-
cyclic monophosphate (cyclic AMP) in neonatal porcine vena
cava (Trevithick et al., 1986; Sumner et al., 1989), hypoten-
sion in anaesthetized rats (Saxena & Lawang, 1985; De Vries
et al., 1997) and cats (Connor et al., 1986) and vasodilatation
in the canine external carotid bed (Villalo´n et al., 1997).
Apart from the implications discussed below, these data
suggest that the 5-HT receptors mediating tachycardia in the
cat may represent a functional correlate of the recombinant
5-ht7 receptor.
Agonist action of some tryptamine derivatives on the
feline heart 5-HT receptor
Admittedly, the rank order of agonist potency (5-CT44 5-
HT45-methoxytryptamine) observed in our study is similar to
that found for the prejunctional sympatho-inhibitory 5-HT1B/1D
receptors mediating canine external carotid vasodilatation
(Villalo´n & Terro´n, 1994). Nevertheless, at these prejunctional
5-HT1B/1D receptors, indorenate and sumatriptan behaved as
agonists (Villalo´n et al., 1993; Villalo´n & Terro´n, 1994), as
previously shown for other 5-HT1B/1D receptors (Saxena &
Villalo´n, 1990; Villalo´n et al., 1990a; 1996; DeVries et al., 1996).
Contrasting with this 5-HT1B/1D receptor operational profile,
our results in the cat heart clearly showed that sumatriptan and
indorenate did not behave as agonists (or antagonists). The
above rank order of agonist potency, therefore, closely resem-
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bles the pharmacological properties of the cloned 5-ht7 receptor
subtype; pKD values obtained for recombinant 5-ht7 receptors
for 5-CT, 5-HT, 5-methoxytryptamine and sumatriptan are 9.5,
8.7, 8.8 and 6.2, respectively (Hoyer et al., 1994).
Do feline heart 5-HT receptors correlate with any
subtype of the 5-HT1 receptor family?
Although the above rank order of agonist potency with in-
dorenate and sumatriptan already excludes the involvement of
5-HT1A, 5-HT1B/1D and sumatriptan-sensitive 5-HT1-like re-
ceptors, it is well known that the 5-HT1 receptor family includes
two additional subtypes, namely, the cloned 5-ht1E and 5-ht1F
receptors (Hoyer et al., 1994). However, the involvement of
these subtypes in the present study is unlikely because (i) 5-CT
and 5-methoxytryptamine, which display very low anity for
the recombinant 5-ht1E and 5-ht1F receptors (Adham et al.,
1993; Hoyer et al., 1994), potently mimicked 5-HT in eliciting
tachycardia; (ii) the tachycardic responses to 5-CT, 5-HT and
5-methoxytryptamine were antagonized by mesulergine and
clozapine, which do not interact with any subtype of the 5-HT1
receptor family (Hoyer et al., 1994); (iii) these tachycardic re-
sponses were not antagonized by GR127935 at doses that are
high enough to block 5-HT1B/1D receptors (De Vries et al., 1996;
Skingle et al., 1996; Villalo´n et al., 1996) and (iv) the 5-HT1
receptor family is, by definition, negatively coupled to adenylyl
cyclase (Hoyer et al., 1994), a signal transduction system
usually associated with vasoconstriction and bradycardia, not
tachycardia (Rand et al., 1987; Saxena & Villalo´n, 1990; 1991;
Sumner et al., 1992).
Lack of resemblance of the feline heart 5-HT receptor
with either 5-HT2, 5-HT3, 5-HT4, 5-ht5 or 5-ht6 receptors
The 5-HT receptors mediating tachycardia in the cat also seem
to dier from the 5-HT2, 5-HT3, 5-HT4 and 5-ht6 receptor
types on the basis of: (i) the high potency of 5-CT relative to
5-HT (present results), an order which is reversed for the
aforementioned types (Hoyer et al., 1994); (ii) insensitivity to
antagonism by high doses of 5-HT2 (ketanserin, ritanserin or
cyproheptadine) and 5-HT3 (MDL 72222) receptor antagonists
(Saxena et al., 1985); (iii) the inactivity (as agonist or antago-
nist) of cisapride (present study), a benzamide with partial
agonist properties at the 5-HT4 receptors mediating tachycar-
dia in the pig (Villalo´n et al., 1991); (iv) resistance to antag-
onism by tropisetron (ICS 205-930) at doses (3000 mg kg71)
that block 5-HT3 and 5-HT4 receptors (Villalo´n et al., 1990b;
1991) and (v) the potent blockade by mesulergine, a compound
showing an almost 300 fold selectivity for the cloned 5-ht7
receptor (pKD=8.2) over the cloned 5-ht6 receptor (pKD=5.8)
(Hoyer et al., 1994). Furthermore, based on the above findings,
the ability of 5-methoxytryptamine to induce tachycardia in
the cat, which is, in its own right, an additional criterion to
exclude the participation of 5-HT3 receptors (Hoyer et al.,
1994), cannot be attributed to its agonist properties at 5-HT4
receptors (Villalo´n et al., 1991).
Interestingly, 5-CT (pKD: 9.5 and 7.4, respectively), me-
thiothepin (pKD: 7.0 and 7.8, respectively) and ergotamine
(pKD: 8.4 and 8.5, respectively) display a relatively high anity
for the recombinant 5-ht5A and 5-ht5B receptors (Hoyer et al.,
1994). This, therefore, raises the question whether the cloned
5-ht5A/5B receptors are related to the 5-HT receptors mediating
tachycardia in the cat. However, this does not seem very likely
because: (i) ergotamine failed to increase heart rate in the cat
(present results) and (ii) methiothepin, which has a ten fold
lower anity than ergotamine for 5-ht5A/5B receptors (see
above), was more potent (not less potent as may be expected
from their anities for 5-ht5A/5B receptors) than ergotamine in
blocking 5-HT-induced feline tachycardia (Saxena, 1988; pre-
sent results). Moreover, the antagonism by mesulergine (pre-
sent results) and metergoline (Saxena, 1988), both with pKD
values of 56.0 at cloned 5-ht5A/5B receptors (Hoyer et al.,
1994), also points against these receptors mediating the 5-HT-
induced tachycardia in the cat.
Resemblance of the feline heart 5-HT receptor to
putative 5-HT7 receptors
Since the involvement of 5-HT1-5-ht6 receptors seems im-
probable, the possibility has finally to be discussed that the
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Figure 5 Eects of a number of drugs acting on 5-HT receptors on tachycardic responses to 5-carboxamidotryptamine (5-CT) in
vagosympathectomized spinal cats. The cumulative doses of various drugs used were: (a) lisuride 100 mg kg71 (n=6), ergotamine
300 mg kg71 (n=6), clozapine 4000 mg kg71 (n=6); (b) mesulergine 1000 mg kg71 (n=6), GR127935 500 mg kg71+tropisetron
3000 mg kg71 (n=5), indorenate 1300 mg kg71+cisapride 1300 mg kg71 (n=4) and sumatriptan 430 mg kg71 (n=3). HR, heart
rate. *P50.05 vs the corresponding control response in animals treated with saline (0.3 ml kg71, n=5), indicated for the sake of
clarity only in (a). Vertical lines show s.e.mean.
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5-HT receptors mediating tachycardia in the cat resemble the
cloned 5-ht7 receptor. Indeed, the rank order of agonist po-
tency of 5-CT44 5-HT45-methoxytryptamine44 cloza-
pine to produce tachycardia in the cat, with sumatriptan and
indorenate inactive (present results) parallels that obtained
with the mouse (Lovenberg et al., 1993; Plassat et al., 1993), rat
(Ruat et al., 1993; Shen et al., 1993) and human (Bard et al.,
1993) cloned 5-ht7 receptors (5-CT45-methoxytryptamine
5 5-HT). Significantly, the above rank order of agonist po-
tency is practically identical to that found in other prepara-
tions where the relaxant eects of 5-HT have been ascribed to
stimulation of musculotropic 5-HT7-like receptors; some of
these preparations include the rabbit femoral vein (Martin &
Wilson, 1995), the Cynomolgus monkey isolated jugular vein
(Leung et al., 1996), the guinea-pig ileum (Carter et al., 1995)
and the canine coronary (Terro´n, 1996) and external carotid
(Villalo´n et al., 1997) arteries.
This suggestion is further strengthened when considering
that the tachycardia induced by 5-HT in the cat was blocked in
previous studies (Saxena, 1988) by methiothepin (pKD: 9.0),
methysergide (pKD: 7.9) and metergoline (pKD: 8.7), com-
pounds that display high anities for cloned 5-ht7 receptors
(Hoyer et al., 1994). On this basis, in the present study, we
deliberately selected ergotamine, lisuride, clozapine and me-
sulergine as potential antagonists because they show either
high anity (the former three) or relative selectivity (the latter)
for the cloned 5-ht7 receptor (see Hoyer et al., 1994). Ac-
cordingly, all of these compounds blocked the 5-CT-, 5-HT-
and 5-methoxytryptamine-induced tachycardic responses,
though this blockade appeared to be highly specific only for
lisuride. Indeed, ergotamine, lisuride, mesulergine or clozapine
have been shown to antagonize smooth muscle relaxant
responses mediated by other functional 5-HT7 receptors (e.g.
Carter et al., 1995; Martin & Wilson, 1995; Terro´n, 1996;
Villalo´n et al., 1997).
Admittedly, there are no selective agonists and antagonists
at cloned 5-ht7 receptors available so far. Thus, although we
recognize that the antagonists blocking 5-HT-induced feline
tachycardia display varying degrees of anity for receptors
other than 5-HT, including a (a1 and a2)-adrenoceptors, H2
histamine and muscarinic receptors (Leysen, 1985), the ago-
nists used in the present study do not interact with these
receptors; most significantly, these and other mechanisms in
5-HT-induced feline tachycardia (including stimulation of
cardiac b-adrenoceptors and the indirect release of catechola-
mines) have already been excluded (Saxena et al., 1985).
In conclusion, it is suggested that the tachycardic eect of
5-HT in the cat is mediated by a receptor similar to the cloned
5-ht7 subtype. Since this cardiac 5-HT receptor represents an-
other functional correlate of the 5-ht7 gene product, the change
of the appellation 5-ht7 for 5-HT7 is favoured. Although spe-
cies variations should not be dismissed (Saxena & Villalo´n,
1991), the present findings in the cat seem to be the first to
show a tachycardic eect being mediated by the 5-HT7 recep-
tor. This in vivo experimental model, which is not complicated
by the presence of other 5-HT receptors, can be utilized to
characterize and develop, including the possibility of studying
oral absorption, new drugs with potential agonist and an-
tagonist properties at functional 5-HT7 receptors.
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